GlassScriptPhysician profile
Michael R Nabity
NPI 1124172663
$1,908.62
in general payments reported to CMS, 2019-2025
26 companies · $411 in 2025
The $411 reported for 2025 was more than what 76% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $245 · 2020: $92.87 · 2021: $261 · 2022: $277 · 2023: $301 · 2024: $321 · 2025: $411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $971 · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $971.39 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $376.95 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $176.89 | 2019-2025 | |
| Organon LLC | $176.63 | 2021-2025 | Nexplanon |
| Sumitomo Pharma America, INC. | $155.10 | 2023-2025 | Myfembree |
| Mayne Pharma Commercial LLC | $116.83 | 2022-2025 | |
| Coopersurgical, INC. | $114.56 | 2020-2025 | Paragard T 380a, Paragard T 380a |
| Astellas Pharma US INC | $107.34 | 2019-2023 | Veozah |
| Biogen, INC. | $98.96 | 2024-2025 | Zurzuvae |
| Hologic Sales and Service, LLC | $82.12 | 2019-2025 | Novasure, Myosure Tissue Removal Device, Acessa Provu System |
| Pfizer INC. | $77.91 | 2019-2023 | |
| Exeltis, USA INC. | $62.41 | 2023-2025 | Slynd, Tyblume |
| Merck Sharp & Dohme LLC | $56.25 | 2021 | |
| Daiichi Sankyo INC. | $50.08 | 2021 | |
| Lilly USA, LLC | $38.04 | 2025 | Zepbound, Mounjaro |
| Novo Nordisk INC | $35.72 | 2025 | Wegovy |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $30.55 | 2019-2021 | |
| Baxter Healthcare | $18.20 | 2025 | Perclot |
| Minerva Surgical, INC | $18.10 | 2025 | |
| Karl Storz Endoscopy-America | $17.81 | 2019 | |
| Evofem Biosciences, INC. | $16.22 | 2022 | |
| Alydia Health | $16.05 | 2021 | |
| Myovant Sciences INC. | $15.29 | 2022 | |
| Avion Pharmaceuticals | $14.28 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $12.61 | 2022 | |
| Currax Pharmaceuticals LLC | $12.22 | 2022 | |
| Duchesnay USA Incorporated | $11.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Nabity listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.